A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma

Annals of Surgery

Volumn 256, Issue 2, 2012, Pages 350-356

  Beasley, Georgia M ^a   Parsons, Colin ^b   Broadwater, Gloria ^a   Selim, M Angelica ^a   Marzban, Suroosh ^b   Abernethy, Amy P ^a   Salama, April K S ^a   Eikman, Edward A ^b   Wong, Terence ^a   Zager, Jonathan S ^b   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

melanoma; PET CT; regional chemotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SURVEILLANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84863819722     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318256d1f5     Document Type: Article

References (50)

1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648. (Pubitemid 32786276)
2. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Amer Coll Surg. 2011;213:306-316.
3. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042-4047.
4. Garbe C, Paul A, Koher-Spath H, et al. Prospective Evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520-529. (Pubitemid 46606483)
5. Ollila D. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919-924. (Pubitemid 44615951)
6. Meyer T, Merkel S, Goehl J, et al. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89:1983-1991.
7. Morton DL,Waneck L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;4:491-499.
8. White RR, Stanley WE, Johnson JL, et al. Long-term survival in 2,505 patients with melanomawith regional lymph node metastasis. Ann Surg. 2002;235:879-887. (Pubitemid 34547308)
9. Fisher S. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998. Laryngoscope. 2002;112:99-110. (Pubitemid 34037745)
10. Badgwell B, Xing Y, Gershenwald JE, et al. Pelvic lymph node dissection is beneficial in subsets of patientswith node-positive melanoma. Ann SurgOncol. 2007;14:2867-2875. (Pubitemid 47460657)
11. Chan AD, Essner R, Wanek LA, et al. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg. 2002;191:16-22.
12. Kretschmer L, Hilgers R, Mohrle M, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004;40:212-218. (Pubitemid 38077023)
13. Young SE, Martinez SR, Faries MB, et al. Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer. 2006;12:207-211. (Pubitemid 43894337)
14. McLoughlin JM, Zager JS, Sondak VK, et al. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008;15:239-247.
15. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Onc. 2006;13:525-532.
16. Tyler DS, Onaitis M, Kherani A, et al. positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019-1025.
17. Swetter SM, Carroll LA, Johnson DL, et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9:646-653. (Pubitemid 34857981)
18. Finkelstein SE, Carrasquillo J, Hoffman JM, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11:731-738. (Pubitemid 40486686)
19. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45:72s-81s.
20. Aukema TS, Valdes Omos RA, Wouters MW, et al. Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol. 2010;17:2773-2778.
21. Macapinlac H. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J. 2004;10:262-270. (Pubitemid 44313555)
22. Antoch G,Vogt FM, Freudenberg LS, et al. Whole-body dualmodality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290:3199-3206. (Pubitemid 38020681)
23. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18 F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178-1186.
24. Dalrymple-Hay MJ, Rome PD, Kennedy C, et al. Pulmonary metastatic melanoma - the survival benefit associated with positron emission tomography screening. Eur J Cardiothorac Surg. 2002;21:611-614.
25. Strobel K, Dummer R, Steinert HS, et al. Chemotherapy response assessment in stage IV melanoma patients - comparison of 18 F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging. 2008;35:1786-1795.
26. Ryan ER, Hill AD, Skehan SJ. FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma. Clin Nucl Med. 2006;31:707-708. (Pubitemid 44624560)
27. Strobel K, Skalsky J, Steinert HC, et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dematology. 2007;215:191-201.
28. Hofman MS, Constantinidou A, Acland K, et al. Assessing response to chemotherapy in metastatic melanoma with FDG PET: early experience. Nucl Med Commun. 2007;12:902-906. (Pubitemid 350306781)
29. Beasley GM, McMahon N, Sanders G, et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer. 2009;115:4766-4774.
30. McMahon N, Beasley G, Sanders G, et al.Aphase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. J Clin Oncol. 2009;27(suppl, abstr 9065).
31. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195-205.
32. Wong TZ, Paulson EK, Nelson RC, et al. Practical approach to diagnostic CT combined with PET imaging. AJR Am J Roentgenol. 2007;188:622-629.
33. Chin BB, Green ED, Turkington TG, et al. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol. 2008;11:118-122.
34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology, Version 1. Fort Washington, PA: NCCN; 2011.
35. Akcali C, Zincirkeser S, Erbagcy Z, et al. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. J Int Med Res. 2007;35:547-553. (Pubitemid 47261118)
36. Sanki A, Scolyer R, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Onc. 2009;35:313-319.
37. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol. 2004;2:155-160. (Pubitemid 38402530)
38. Petersen RP, Hanish S, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133:104-110.
39. Andrews S, Robinson L, Cantor A, et al. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. Cancer Control. 2006;13:218-223. (Pubitemid 44469743)
40. Wasif N, Bagaria SP, Ray P, et al. Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Onc. 2011;104:111-115.
41. Kern K. [14C] deoxygluocse uptake and imaging in malignant melanoma. J Surg Res. 1991;50:643-647.
42. Wahl RL, Hutchins GD, Buchsbaum DJ, et al. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: feasibility studies for cancer imaging with positron-emission tomography. Cancer. 1991;47: 1544-1550.
43. Mijnhout GS, Hoekstra OS, van Tulder MW, et al. Systematic review of the diagnostic accuracy of [18F] fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530-1542. (Pubitemid 32319265)
44. Wagner JD, Schauwecker D, Hutchins G, et al. I, Initial assessment of positron emission tomography for the detection of subclinical regional lymphatic metastasis in melanoma. J Surg Oncol. 1997;64:181-189. (Pubitemid 27157405)
45. Nathansohn N, Schacter J, Gutman H, et al. Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg. 2005;140:1172-1177. (Pubitemid 41815899)
46. Lee RJ, Gibbs JF, Proulx GM, et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2000;62:467-474. (Pubitemid 30067798)
47. Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrentmelanoma? Ann Surg. 2003;238:743-747. (Pubitemid 38182267)
48. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706-715; discussion 715-717.
49. Koops S, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 1998;16: 2906-2912.
50. Kroon HM, Moncrieff M, Kam PC, et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15: 3003-3013.